ABO-histo blood group incompatibility in hematopoietic stem cell and solid organ transplantation

被引:24
作者
Stussi, Georg
Halter, Joerg
Schanz, Urs
Seebach, Joerg D.
机构
[1] Univ Zurich Hosp, Lab Transplantat Immunol, Dept Internal Med, CH-8091 Zurich, Switzerland
[2] Univ Basel Hosp, Dept Internal Med, CH-4031 Basel, Switzerland
[3] Univ Zurich Hosp, Clin Hematol, Dept Internal Med, CH-8091 Zurich, Switzerland
关键词
D O I
10.1016/j.transci.2006.05.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In contrast to solid organ transplantation (SOT), ABO-histo blood group incompatibility is of minor importance for hematopoietic stem cell transplantation (HSCT). Patients receiving ABO-incompatible HSCT are at an increased risk for immune-mediated hematological complications including immediate and delayed hemolysis, late red blood cell engraftment and pure red cell aplasia, but seem not to have a worse overall survival or increased transplant-related mortality. This review gives an overview of the immunological mechanisms leading to complications associated with ABO-incompatible HSCT and describes approaches to prevent them. The current organ shortage in SOT stimulates the exploration of new strategies to expand the donor pool including ABO-incompatible SOT and xenotransplantation. Here, we discuss the hypothesis that ABO-incompatible transplantation may be viewed as a human in vivo model for the humoral immune mechanisms of antigen-mismatched transplantation. ABO-incompatible HSCT and SOT provide excellent possibilities to analyze graft accommodation and transplantation tolerance. Understanding the underlying mechanisms of graft survival in ABO-incompatible transplantation may facilitate new strategies to overcome the immunological barriers in SOT and xenotransplantation. (c) 2006 Published by Elsevier Ltd.
引用
收藏
页码:59 / 69
页数:11
相关论文
共 106 条
[31]   The second century of ABO: and now for something completely different [J].
Heal, JM ;
Blumberg, N .
TRANSFUSION, 1999, 39 (11-12) :1155-1159
[32]   ABH ANTIGENS AND BONE-MARROW TRANSPLANTATION [J].
HERSHKO, C ;
GALE, RP ;
HO, W ;
FITCHEN, J .
BRITISH JOURNAL OF HAEMATOLOGY, 1980, 44 (01) :65-73
[33]  
HO WG, 1984, BRIT J HAEMATOL, V57, P155, DOI 10.1111/j.1365-2141.1984.tb08509.x
[34]  
HOWS J, 1986, BLOOD, V67, P177
[35]   Anti-AB titer changes in patients with ABO incompatibility after living related kidney transplantations - Survey of 101 cases to determine whether splenectomies are necessary for successful transplantation [J].
Ishida, H ;
Koyama, I ;
Sawada, T ;
Utsumi, K ;
Murakami, T ;
Sannomiya, A ;
Tsuji, K ;
Yoshimura, N ;
Tojimbara, T ;
Nakajima, I ;
Tanabe, K ;
Yamaguchi, Y ;
Fuchinoue, S ;
Takahashi, K ;
Teraoka, S ;
Ito, K ;
Toma, H ;
Agishi, T .
TRANSPLANTATION, 2000, 70 (04) :681-685
[36]  
KALAYCIOGLU M, 1995, BONE MARROW TRANSPL, V15, P105
[37]   Long-term follow-up of ABO-incompatible renal transplant recipients [J].
Karakayali, H ;
Moray, G ;
Demirag, A ;
Turan, M ;
Bilgin, N ;
Haberal, M .
TRANSPLANTATION PROCEEDINGS, 1999, 31 (1-2) :256-257
[38]   Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: Effect of HLA disparity, ABO incompatibility, and method of T-cell depletion [J].
Keever-Taylor, CA ;
Bredeson, C ;
Loberiza, FR ;
Casper, JT ;
Lawton, C ;
Rizzo, D ;
Burns, WH ;
Margolis, DA ;
Vesole, DH ;
Horowitz, M ;
Zhang, MJ ;
Juckett, M ;
Drobyski, WR .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 (11) :620-630
[39]   Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation [J].
Kim, JG ;
Sohn, SK ;
Kim, DH ;
Baek, JH ;
Lee, KB ;
Min, WS ;
Kim, CC ;
Lee, MH ;
Lee, JJ ;
Chung, IJ ;
Kim, HJ ;
Lee, JW .
BONE MARROW TRANSPLANTATION, 2005, 35 (05) :489-495
[40]  
KLUMPP TR, 1991, BONE MARROW TRANSPL, V8, P159